Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline

Dapagliflozin is a highly selective sodium-glucose cotransporter 2 inhibitor associated with stabilization of estimated glomerular filtration rate (eGFR); reductions in glycated hemoglobin (HbA1c), systolic blood pressure, body weight, and albuminuria; and a small and consistent increase in hematocr...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefánsson, Bergur V., Heerspink, Hiddo J.L., Wheeler, David C., Sjöström, C. David, Greasley, Peter J., Sartipy, Peter, Cain, Valerie, Correa-Rotter, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255174/
https://www.ncbi.nlm.nih.gov/pubmed/34258337
http://dx.doi.org/10.1016/j.dib.2021.107237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255174/
https://www.ncbi.nlm.nih.gov/pubmed/34258337
http://dx.doi.org/10.1016/j.dib.2021.107237

Ejemplares similares